Innovation is in our genes.

SPECT-Guided CT in Bone Scintigraphy

SPECT-Guided CT for Evaluating Foci of

Increased Bone Metabolism Classified as

Indeterminate on SPECT in Cancer Patients

W. Römer, A. Nömayr, M Uder, W. Bautz, T. Kuwert

University of Erlangen, Germany

JNM, Vol. 47, No. 7, July 2006

Retrospective study done using the Siemens

Symbia T2 TruePoint SPECT•CT system

Innovation is in our genes.

We see away to ...

eliminate 90% of indeterminate

SPECT oncology scans

Innovation is in our genes.

Summary

52 bone lesions in 44 patients of known cancer were

rated as indeterminate with SPECT alone. Majority

of the indeterminate lesions were in ribs and the

scapula.

When corresponding SPECT•CT images were

analyzed, 92% of the indeterminate lesions were

classified as definitively benign or definitively

malignant based on correlation between SPECT and

CT findings. Only 8% (4 lesions out of 52) remained

indeterminate after analysis of SPECT·CT images.

Innovation is in our genes.

Study Results and Conclusion

SPECT-guided CT was able to clarify more than 90%

of SPECT findings classified as indeterminate*,

thus considerably shortening the diagnostic

process.

SPECT-guided CT has the potential to reduce

patient radiation exposure, by limiting the CT scan

to the body region of interest identified by SPECT.

* In an analysis blinded to clinical pretest probability and planar scans.

Innovation is in our genes.

Proven Outcomes

More than 90% of cancer patients leave the clinic with a definite diagnosisWolfgang Römer, MD, University Clinic of Nuclear Medicine, Erlangen, Germany

Malignant

Indeterminate

Benign

44

52

28

0

25

50

75

100

125

SPECT

Lesions

43

77

SPECT•CT

4

SPECT vs. SPECT•CT Diagnostic in Oncology

Innovation is in our genes.

Siemens Molecular Imaginginnovation is in our genes.